MeiraGTx Holdings plc Selling and Marketing Expense
MeiraGTx Holdings plc (MGTX) reported Selling and Marketing Expense of $198.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-05-14
- MeiraGTx Holdings plc selling and marketing expense for the quarter ending 2026-03-31 was $198.00K, a 85.63% decline year-over-year.
- MeiraGTx Holdings plc selling and marketing expense for the quarter ending 2025-12-31 was $476.00K, a 95.97% decline year-over-year.
- MeiraGTx Holdings plc selling and marketing expense for the quarter ending 2025-09-30 was $313.00K, a 97.39% decline year-over-year.
- MeiraGTx Holdings plc selling and marketing expense for the quarter ending 2025-06-30 was $2.68M.
- MeiraGTx Holdings plc selling and marketing expense for fiscal 2025 was $4.84M, a 79.64% decline from fiscal 2024.
- MeiraGTx Holdings plc selling and marketing expense for fiscal 2024 was $23.79M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $198.00K 10-Q · filed 2026-05-14 | $674.00K derived: sum of 2 quarters · filed 2026-05-14 | $987.00K derived: sum of 3 quarters · filed 2026-05-14 | $3.66M derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | $476.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $789.00K derived: sum of 2 quarters · filed 2026-03-30 | $3.46M derived: sum of 3 quarters · filed 2026-03-30 | $4.84M 10-K · filed 2026-03-30 |
| 2025-09-30 | $313.00K 10-Q · filed 2025-11-13 | $2.99M derived: sum of 2 quarters · filed 2025-11-13 | $4.37M 10-Q · filed 2025-11-13 | $16.17M derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-06-30 | $2.68M 10-Q · filed 2025-08-14 | $4.05M 10-Q · filed 2025-08-14 | $15.86M derived: sum of 3 quarters · filed 2026-05-14 | $27.84M derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-03-31 | $1.38M 10-Q · filed 2026-05-14 | $13.18M derived: sum of 2 quarters · filed 2026-05-14 | $25.17M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $11.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $23.79M derived: sum of 2 quarters · filed 2026-03-30 | $23.79M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $11.98M 10-Q · filed 2025-11-13 | $11.98M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |